The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gained from trials so far?

Levis provides an overview of the key FLT3 inhibitors in clinical development for the treatment of FLT3-mutated (FLT3m) AML and discusses ongoing questions, including how to select the most appropriate FLT3 inhibitor for different patient populations and how best to incorporate them into standard treatment regimens. He highlights the value of measurable residual disease (MRD) in monitoring disease status as an important insight from clinical trials.

This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of AML?

Stein summarizes the approved indications for currently available FLT3 inhibitors and considers potential future directions for their investigation in the treatment of acute myeloid leukemia (AML), including in combination regimens and in patients with FLT3-ITD-negative AML.

This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trials addressing these?

Craddock begins by highlighting the progress made in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML) over the past decade with two large randomized clinical trials: the phase III RATIFY (NCT00651261) trial, investigating the addition of midostaurin to standard chemotherapy in patients with newly diagnosed (ND) FLT3m AML; and the phase III QuANTUM-First (NCT02668653) trial, assessing the addition of quizartinib to standard chemotherapy in patients with ND FLT3-internal tandem duplication (FLT3-ITD) AML. He discusses data from trials aiming to further improve outcomes for patients with FLT3m AML and considers whether similar benefit can be demonstrated in patients requiring less intensive regimens.

This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.